X
Xiaomei Zhang
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 4
Citations - 5121
Xiaomei Zhang is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Receptor tyrosine kinase & Mitogen-activated protein kinase. The author has an hindex of 3, co-authored 4 publications receiving 4797 citations.
Papers
More filters
Journal ArticleDOI
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott Wilhelm,Christopher A. Carter,LiYa Tang,Dean Wilkie,Angela McNabola,Hong Rong,Charles Chen,Xiaomei Zhang,Patrick Vincent,Mark McHugh,Yichen Cao,Jaleel Shujath,Susan Gawlak,Deepa Eveleigh,Bruce Rowley,Li Liu,Lila Adnane,Mark Lynch,Daniel Auclair,Ian W. Taylor,Rich Gedrich,Andrei Voznesensky,Bernd Riedl,Leonard Post,Gideon Bollag,Pamela A. Trail +25 more
TL;DR: Data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
Journal ArticleDOI
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Li Liu,Yichen Cao,Charles Chen,Xiaomei Zhang,Angela McNabola,Dean Wilkie,Scott Wilhelm,Mark Lynch,Christopher A. Carter +8 more
TL;DR: The results suggest that the antitumor activity of sorafenib in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).
Patent
Urea compounds useful in the treatment of cancer
Roger A. Smith,Holia Hatoum-Mokdad,Louis David Cantin,Donald Bierer,Wenlang Fu,Dhanapalan Nagarathnam,Gaetan H. Ladouceur,Yamin Wang,Herbert Ogutu,Scot Wilhelm,Ian W. Taylor,Sanjeeva P. Reddy,Richard W. Gedrich,Christopher A. Carter,Aaron Schmitt,Xiaomei Zhang +15 more
TL;DR: Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them are discussed in detail in this paper, where the authors present a method for using them to treat cancer.
Journal Article
BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells
Daniel Auclair,Donna Miller,Christopher A. Carter,Yong Chang,Barbara Polony,Xiaomei Zhang,Victoria Yatsula,Walter Pickett,Timothy Housley,Amy Burd,Hong Shi,Sandy Rocks,Richard Gedrich,Laura Abriola,Don Apanovitch,Istvan Enyedy,Jacques Dumas,Bernd Riedl,Pamela A. Trail,Scott Wilhelm +19 more
TL;DR: The demonstration that BAY 43-9006 exhibits potent target inhibition and efficacy inFLT3-ITD models suggests that this compound may have biologic activity in AML patients with FLT3 mutations.